Abstract
BackgroundThe present clinical field trial was conducted to assess the efficacy of a broad-spectrum parasiticide spot-on formulation containing eprinomectin (Broadline®) against Thelazia callipaeda eyeworm in naturally infected cats.MethodsFifteen privately owned cats harboring at least one live adult T. callipaeda were included in the study. Cats were randomly allocated to an untreated control group of seven cats or to a Broadline®-treated group of eight cats. Cats were treated on Day 0; ocular examinations were performed at inclusion and on Days 7 and 14; eyeworms were recovered and counted on Day 14. The primary efficacy assessment was based on group comparison of number of T. callipaeda on Day 14.ResultsSeven days after treatment, six of eight treated cats were negative for eyeworm infection per visual examination, and on Day 14 no eyeworms were found in the treated cats while the seven untreated cats were still infected (geometric mean: 1.97). All cats had inflammatory ocular signs at inclusion; on Day 14, five of eight treated cats had recovered while all untreated control cats were still symptomatic. All collected parasites were confirmed to be T. callipaeda by morphology and molecular characterization.ConclusionsA single treatment with Broadline® provided 100% efficacy against feline thelaziosis and improved related ocular inflammation signs.Graphical abstract
Highlights
The present clinical field trial was conducted to assess the efficacy of a broad-spectrum parasiticide spot-on formulation containing eprinomectin (Broadline®) against Thelazia callipaeda eyeworm in naturally infected cats
At the end of the study, all cats in the control group were still infected with T. callipaeda while all cats in Group 2 (G2) were free of infection
There were significantly fewer worms in G2 compared to Group 1 (G1) (p < 0.05) (Tables 2, 3) resulting in a 100% efficacy rate
Summary
The present clinical field trial was conducted to assess the efficacy of a broad-spectrum parasiticide spot-on formulation containing eprinomectin (Broadline®) against Thelazia callipaeda eyeworm in naturally infected cats. Adult parasites (“eyeworms”) reside in the conjunctival sac and underneath the third eyelid [5]. Previous studies have demonstrated the efficacy and safety of topical [12] and oral [13] formulations, therapeutic options for the treatment of feline thelaziosis are limited. The efficacy of the macrocyclic lactone eprinomectin against bovine thelaziosis caused by Thelazia rhodesi has been recently demonstrated [14]. The present study aimed at assessing for the first time the efficacy of Broadline®, a broad-spectrum parasiticide which comprises eprinomectin, combined with fipronil, (S)-methoprene and praziquantel, for the treatment of natural acquired cat thelaziosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
